DNA topoisomerase IIα and Ki-67 in human adrenocortical neoplasms: A possible marker of differentiation between adenomas and carcinomas

Modern Pathology

Volumn 10, Issue 9, 1997, Pages 901-907

  Iino, Kazumi ^a,b   Sasano, Hironobu ^a   Yabuki, Noritaka ^a   Oki, Yutaka ^b   Kikuchi, Akihiko ^c   Yoshimi, Teruya ^b   Nagura, Hiroshi ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c MITSUBISHI KASEI INST OF LIFE SCI   (Japan)

Author keywords

Adrenal cortex; Carcinoma; Cell proliferation; Immunohistochemistry; Ki 67; Topoisomerase II

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); KI 67 ANTIGEN; MONOCLONAL ANTIBODY;

ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADULT; AGED; ARTICLE; CELL CYCLE; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL;

ADENOMA; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL HYPERFUNCTION; ADULT; AGE FACTORS; AGED; ANTIGENS, NEOPLASM; CARCINOMA; CELL DIVISION; CHILD, PRESCHOOL; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; EVALUATION STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0030765406     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Nakano M. Adrenal cortical carcinoma: a clinicopathological and immunohistochemical study of 91 autopsy cases. Acta Pathol Jpn 1988;38:163-80.
2. Hough AJ, Hollifield JW, Page DL, Hartmann WH. Prognostic factors in adrenal cortical tumors. Am J Clin Pathol 1979;72: 390-8.
3. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 1984;8:163-9.
4. Sasano H, Imatani A, Shizawa S, Suzuki T, Nagura H. Cell proliferation and apoptosis in normal and pathologic human adrenal. Mod Pathol 1995;8:11-7.
5. Suzuki T, Sasano H, Nishikawa T, Rhame J, Wilkinson DS, Nagura H. Discerning malignancy in human adrenocortical neoplasms: utility of DNA flow cytometry and immunohistochemistry. Mod Pathol 1992;5:224-30.
6. Goldblum JR, Shannon R, Kaldjian EP, Thiny M, Davenport R, Thompson N, et al. Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms. Mod Pathol 1993;6:663-8.
7. Gerdes J, Lemke H, Baisch H, Wacker H-H, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-5.
8. Heck MM S, Hittelman WN, Earnshaw WC. Differential expression of DNA topoisomerase I and II during the eukaryotic cell cycle. Proc Natl Acad Sci U S A 1988;85: 1086-90.
9. Yabuki N, Sasano H, Katsuaki K, Ohhara S, Toyota T, Nagura H, et al. Immunohistochemical study of DNA topoisomerase II in human gastric disorders. Am J Pathol 1996;149:997-1007.
10. Reincke M, Nieke J, Krestin GP, Saeger W, Allolio B, Winkelmann W. Preclinical Cushing's syndrome in adrenal "incidentalomas": comparison with adrenal Cushing's syndrome. J Clin Endocrinol Metab 1992;75:826-32.
11. Newell-Price J, Grossman A. Adrenal incidentaloma: subclinical Cushing's syndrome. Postgrad Med J 1996;72:207-10.
12. Hall PA, Levison DA, Woods AL, Yu CC-W, Kellock DB, Watkins JA, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990;162:285-94.
13. Drake FH, Zimmerman JP, McCabe FL, Bartus HF, Per SR, Sullivan DM, et al. Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. J Biol Chem 1987; 262:16739-47.
14. Tuccari G, Rizzo A, Giuffre G, Barresi G. Immunocytochemical detection of DNA topoisomerase type II in primary breast carcinomas: correlation with clinico-pathological features. Virchows Archiv A Pathol Anat Histopathol 1993;423: 51-5.
15. Holden JA, Perkins SL, Snow GW, Kjeldsberg CR. Immunohistochemical staining for DNA topoisomerase II in non-Hodgkin's lymphomas. Am J Clin Pathol 1995;104:54-9.
16. Ito K, Sasano H, Yabuki N, Matsunaga G, Saito S, Kikuchi A, et al. Immunohistochemical study of Ki-67 and DNA topoisomerase II in human endometrium. Mod Pathol 1997;10: 289-94.
17. Forgt F, Gibbons D, Hallgrimsson J, Holden J, Alder SL, O'Brien MJ. Comparison of topoisomerase IIα and MIB-1 expression in benign, dysplastic, and malignant gastric mucosal biopsies [abstract]. Mod Pathol 1993;9:63A.
18. Zijlstra JG, Dejong S, Devries EGE, Mulder NH. Topoisomerase: new targets in cancer chemotherapy. Med Oncol Tumor Pharmacother 1990;7:11-8.
19. Zwelling LA. DNA topoisomerase II as a target of antineoplastic drug therapy. Cancer Metastasis Rev 1985;4:263-76.
20. Fry AM, Chresta CM, Davies SM, Walker MC, Harris A, Hartley JA, et al. Relationship between topoisomerase II level and chemosensitivity in chemosensitivity in human tumor cell lines. Cancer Res 1991;51:6592-5.
21. Feldhoff PW, Mirski SEL, Cole SP, Sullivan DM. Altered subcellular distribution of topoisomerase IIα in a drug-resistant human small cell lung cancer cell line. Cancer Res 1994;53: 756-62.
22. Mattern J, Volm M. Prediction of drug resistance in human tumors using immunohistochemical techniques. Anticancer Res 1992;12:413-8.